Showing results (251-260 of 317) with videos related to

Sort By:
Pageof 32
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Current Medicinal Chemistry|February 20, 2025
Evaluation of Antiseptic Drug Candidate Pyridosept in Preclinical in Vitro StudiesRenata Kazakova, Alfiya Iksanova, Mariya Agafonova, et al.
The Oncologist|March 11, 2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate CancerMeredith N Freeman, Albert Jang, Jason Zhu, et al.
BMC Medical Genomics|September 19, 2020
A sporadic case of congenital aniridia caused by pericentric inversion inv(11)(p13q14) associated with a 977 kb deletion in the 11p13 regionTatyana A Vasilyeva, Andrey V Marakhonov, Marina E Minzhenkova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Lancet. Oncology|November 3, 2023
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
The Journal of Clinical Investigation|June 26, 2018
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancerMohammad Alyamani, Hamid Emamekhoo, Sunho Park, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
Pageof 32